BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. 

BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. 

Under the terms of the settlement agreement, AbbVie will pay BTL an undisclosed payment. The details of the agreement are confidential and will not be disclosed. All litigation pending between the parties will be dismissed. 

"We are very pleased with the outcome of this settlement," says Ron Borsheim, VP of Business Development, in a news release. "BTL will continue to vigorously defend BTL patents and our customers' investment into the Emsculpt family of products."